Additionally, the population of tumor-infiltrating CD8+ T cells was higher in mice treated with CXCR3-CD8+ T cells (21.42%) than in those treated with PBS (5.94%) or pLenti-CD8+ T cells (12.05%; Fig. 7D). The gene discussed is CXCR3; the disease is neoplasm.